last week , Argentina recorded a 54% increase in COVID-19 cases. This increase was related to the presence of the BA.2 subfactor of μM. However, the latest report issued by country project for genomic surveillance of coronavirus, which relies on Ministry of Science, Technology and InnovationAnd People with BA.4 and BA.2.12.1 subspecies, mutations that lead to infection, have been detected in the United States and South Africa.
According to a report by this group of Argentine scientists, it was not only in recent weeks that Omicron BA.2 variant, but has also become mainstream. The experts explained this in the report After the BA.1 strain was detected in 100% of Buenos Aires cases, this new mutation increased its presence from 69.4% to 87% in just two weeks. While “BA.4 Case constitutes the first detection in South America”.
“COVID-19 cases are increasing due to various factors. There is a slowdown in vaccination with booster doses and It is known that only two doses of the vaccines applied today are not sufficient against exposure to the Omicron variant and its sublines, which are more transmissible.confirmed Infobae the doctor Edward Lopezdirector of the Pediatric Infectious Diseases Course at the University of Buenos Aires Medical School and Ricardo Gutierrez Children’s Hospital in Buenos Aires.
In this sense, the report highlights the importance strains BA.4, BA.5 and BA.2.12.1, which have received special attention worldwide for being associated with an “increase in the number of cases in South Africa (BA.4 and BA.5) and in the United States (BA.2.12. 1) and offset of BA.2 ratios, which in turn has been reported to be more transmissible than BA.1″.
These strains have acquired some additional mutations that could affect their biological characteristics (BA.4 and BA.5 include important spike protein mutations: del 69/70, L452R and F486V, and BA.2.12.1, L452Q mutations). S704L)”, they explained in the document, while stating that “according to GISAID data and WHO reports, BA.4 ratios have not yet been reported in South America, while BA.2.12.1 ratios have only recently been detected in Peru and Colombia within countries of the regionThe situation modified in the first boom thanks to this scientific observation.
On this last point, the Country Project highlighted that “Three cases of two emerging micron strains have been revealed of recent global interest due to their association with an increase in cases and immune evasion., one belongs to lineage BA.4 and two to BA.2.12.1; Emerging lineages that have not yet been reported in our country.”
In this context, Dr. Lopez warned that with the change in testing criteria, there are undiagnosed cases. “Some jurisdictions are doing less testing and there will be unreported cases. We need to be alert to the hospitalization status due to COVID-19, especially due to the progression of the Ómicron BA.2 variant or other substrains, s It is important to remind the population to go for the booster shots at this time.” Infobae.
City of Buenos Aires, Emerging Pedigree BA 4: As stated in the document, This is a 28-year-old patient with no relevant history. “He was consulted for presenting an oppressive headache associated with severe eye pain, abdominal pain and stabbing and a feverish history. Complete COVID-19 vaccination schedule with two doses of Sinopharm,” the letter states. In this sense, they explained that on a physical examination, this person showed a saturation of 98% of the ambient air, which resulted in a positive result for COVID-19. “It does not refer to trips abroad or contact with people who have traveled abroad‘, they confirmed.
City of Buenos Aires, Emerging Pedigree BA.2.12.1: in this case it is a A patient over 60 years old with a history of hypertension and insulin resistance, who had “moderate COVID-19 infection with asthenia (fatigue), sore throat (sore throat) and congestion, to which he added a sub-record.” He was vaccinated with 3 doses (2 AstraZeneca + Pfizer, last on 21/12) and “There is no information regarding travel history abroad or close contact with the traveler“.
Chaco, Emerging Lineage BA.2.12.1: he is A patient over 60 years old, without comorbidities, with a complete vaccination schedule against COVID-19 (two doses of Sinopharm and First Ref Pfizer). As they explain, he exhibited “high respiratory symptoms (runny nose/low-grade fever/headache) for 72 hours from development, and adhered to home isolation for a full 7 days without experiencing subsequent clinical complications.” “As a matter of interest, he refers to close contact with two of his relatives, both showing symptoms, days before he developed symptoms. One of them kept Contact with a symptomatic patient who arrived in early April from Mexico‘, they shed light.
“The BA.4 case constitutes the first discovery in South America“highlighted the scientists and concluded: “The three described cases constitute sporadic cases so far, however, it is necessary to follow their evolution over time to analyze whether these strains will be relevant in our country”, since “the pedigree of BA.2.12.1 has not Shows evidence that they belong to a common in-country chain of transmission ‘but’Provide a relative association with various North American sequences“.